Item 8.01 Other Events.

On January 7, 2021, Aquestive Therapeutics, Inc. (the "Company") issued a press release providing a business update, including relating to the resubmission of a revised dosing regimen to the FDA for the Company's drug candidate Libervant in December 2020 and a completed pharmacokinetic trial for the Company's drug candidate AQST-108. A copy of the Company's press release is attached hereto as Exhibit 99.1 and incorporated into this Item 8.01 by reference.

Item 9.01 Financial Statements and Exhibits





 (d) Exhibits.



Exhibit Number   Description

  99.1           Press Release dated January 7, 2021.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses